Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial

BACKGROUND: Immune checkpoint inhibitors monotherapy has been studied in patients with advanced biliary tract cancer (BTC). The aim of this study was to assess the efficacy and safety of camrelizumab, plus gemcitabine and oxaliplatin (GEMOX) as first-line treatment in advanced BTC and explored the p...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:J Immunother Cancer
المؤلفون الرئيسيون: Chen, Xiaofeng, Wu, Xiaofeng, Wu, Hao, Gu, Yanhong, Shao, Yang, Shao, Qianwen, Zhu, Feipeng, Li, Xiao, Qian, Xiaofeng, Hu, Jun, Zhao, Fengjiao, Mao, Weidong, Sun, Jing, Wang, Jian, Han, Gaohua, Li, Changxian, Xia, Yongxiang, Seesaha, Poshita Kumari, Zhu, Dongqin, Li, Huajun, Zhang, Junling, Wang, Guoqiang, Wang, Xuehao, Li, Xiangcheng, Shu, Yongqian
التنسيق: Artigo
اللغة:Inglês
منشور في: BMJ Publishing Group 2020
الموضوعات:
Clinical/Translational Cancer Immunotherapy
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC7656907/
https://ncbi.nlm.nih.gov/pubmed/33172881
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001240
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة